1 / 12
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Port Dressing, 1665R, 12 cm x 12 cm, 25/CAR, 4 CAR/CS, 100/CS
R299
Out of Stock
Get Notified When Back in Stock
Join the waitlist for 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Port Dressing, 1665R, 12 cm x 12 cm, 25/CAR, 4 CAR/CS, 100/CS and we'll email you as soon as it's available again.
We'll send you one email when this item is back in stock.
No spam, just a single notification.
Express — as soon as 24 hours* from R199
Economy R99, 3–6 working days · free over R3 000
R45 to your res at UCT & Stellenbosch
Free collection in Cape Town, Mon–Fri 10–4
7-day returns on defective or wrong items
Secure checkout · card, EFT or 4 instalments with Payflex
* Order early, stock permitting. Express averages 2–4 working days; regional and rural areas add 1–2 days.
Categories
You might also like
All Consumables
- IV port dressing plus CHG gel pad offers antimicrobial protection with the comfort your patients deserve.
- Tegaderm CHG I.V. Dressing is intended to reduce catheter-related bloodstream infections (CRBSIs) in patients with central venous or arterial catheters.
- CHG gel pad provides immediate and continuous antimicrobial activity – reducing skin flora and preventing its regrowth – for up to 7 days.
- Dressing is easy to remove with adhesive-free window minimising adhesive contact with non-coring needle and patient’s skin.
- Transparent dressing and CHG gel pad allow continuous site visibility to easily assess for early signs of infection.
- CHG gel pad conforms around the needle and stays in contact with the skin.
- Accommodates implanted venous ports and a variety of non-coring Huber needles.
- Picture-frame delivery makes placement accurate and easy, minimising potential to stick to gloves or to itself.
The Tegaderm CHG Chlorhexidine Gluconate I.V. port dressing, 1665R, is an antimicrobial (CHG) gel pad plus IV port dressing specifically designed to protect single or double implanted venous portsand non-coring needles. It combines antimicrobial protection with site visibility, catheter securement and consistent applicationfor patients with implanted venous ports, including oncology and haematology patients.